Anacalypsis Therapeutics

ATx is a private discovery stage small-medium enterprise (registered Private Company (PC) or IKE in Greece), focusing on therapeutic and biomarker development for Parkinson's disease and other currently incurable neurodegenerative diseases. ATx was established in 2019, deriving from the academic research of Drs. Rideout and Polissidis, at the Biomedical Research Foundation of the Academy of Athens (BRFAA). Strong research ties are maintained between the company and BRFAA, as well as multiple Neurology clinics at hospitals throughout Athens. Cellular and in vivo models are used to identify and evaluate novel gene and pathway based therapeutic targets to block neuronal death in PD. Drug development efforts are closely tied to biomarker development as we believe that this dual approach is key for optimal patient treatment (giving the right drug to the right patient at the right time).